Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Placebo-Controlled, Phase I, Pilot Clinical Trial to Evaluate the Safety and Immunogenicity of ENV 2-3, a Yeast-Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59 in Individuals With HIV Infection (Placebo Patients Receive MF59 Emulsion Only)

This study has been completed.
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID) Identifier:
First received: November 2, 1999
Last updated: May 17, 2012
Last verified: May 2012
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: September 1995
  Estimated Primary Completion Date: No date given